Ionis Pharmaceuticals To Expedite Development Of Rare Neurological Disease Candidate With FDA Breakthrough Status
1. FDA granted Breakthrough Therapy designation to Ionis's ION582 for Angelman syndrome. 2. ION582 showed significant improvements in communication and motor function. 3. Ionis launched the Phase 3 REVEAL study for ION582, targeting enrollment by 2026. 4. Analysts view the BTD as a win for Ionis's neurology division. 5. IONS stock rose 4.68% after the announcement, reflecting positive investor sentiment.